715
Participants
Start Date
June 13, 2016
Primary Completion Date
August 14, 2018
Study Completion Date
September 11, 2018
Mirabegron
Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.
Placebo
Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.
Tamsulosin Hydrochloride
Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
Site US01015, Garden City
Site US01019, Plainview
Site DE49001, Hagenow
Site US01041, Baltimore
Site US01063, Newport News
Site IT39001, Treviglio
Site US01069, Cary
Site ES34009, Lugo
Site ES34001, Madrid
Site US01079, Maiden
Site US01026, Pompano Beach
Site US01027, Wellington
Site US01025, St. Petersburg
Site US01009, Homewood
Site US01005, Huntsville
Site ES34004, Vigo
Site US01042, Clarksville
Site US01072, Bristol
Site US01056, Knoxville
Site US01075, Knoxville
Site US01078, Knoxville
Site ES34002, Seville
Site ES34006, Valencia
Site DE49002, Duisburg
Site IT39004, Florence
Site US01034, West Des Moines
Site IT39006, Pisa
Site US01067, Billings
Site US01060, Kansas City
Site IT39010, Chieti
Site IT39008, Vasto
Site FR33004, Colmar
Site US01061, Omaha
Site FR33002, Pierre-Bénite
Site US01094, Shreveport
Site CZ42001, Sternberk
Site US01097, Englewood
Site IT39002, Avellino
Site US01031, Albuquerque
Site IT39003, Catanzaro
Site US01081, Los Angeles
Site US01070, Hawaiian Gardens
Site US01064, Valley Village
Site US01068, San Diego
Site US01021, Murrieta
Site US01012, Anchorage
Site US01016, Boston
Site US01003, Watertown
Site US01029, Edison
Site CA15008, Calgary
Site CA15003, Barrie
Site CA15001, Brampton
Site CA15005, Toronto
Site CA15011, Québec
Site CA15002, Sherbrooke
Site CA15009, Sherbrooke
Site CA15014, Victoriaville
Site CZ42004, Benešov
Site CZ42006, Domažlice
Site CZ42005, Prague
Site CZ42003, Prague
Site DE49003, Eisleben Lutherstadt
Site DE49006, Halle
Site DE49004, Hamburg
Site DE49005, Hettstedt
Site DE49007, Sangerhausen
Site IT39005, Latina
Site PL48006, Katowice
Site PL48001, Piaseczno
Site PL48004, Warsaw
Site PL48005, Wroclaw
Site PL48007, Wroclaw
Site ES34007, Barcelona
Site ES34003, Miranda de Ebro
Site GB44005, Bristol
Site GB44011, Bristol
Site GB44004, Newcastle upon Tyne
Site GB44002, Reading
Site GB44006, York
Astellas Pharma Global Development, Inc.
INDUSTRY